ARWR Earnings Date: Nov 24, 2026 (Estimated) — Arrowhead Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARWR's next earnings date?
Arrowhead Pharmaceuticals, Inc. (ARWR) is expected to report Q4 2026 earnings on Tuesday, November 24, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.52 on revenue of $61.2M.
How did ARWR do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q3 2026), Arrowhead Pharmaceuticals, Inc. posted EPS of -$1.36 versus the -$1.28 estimate, a miss of 14.3%. Revenue was $75.3M against a $44.2M estimate. The stock's 1-day post-earnings move was -3.0%.
How much does ARWR stock move after earnings?
ARWR beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.6% (up or down) in the day after earnings.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q3 2026 | -1.28 | -1.36 | -14.29% | $75.3M | ❌ Miss | -2.99% | -0.39% | -4.71% |
| 2026-05-07 | Q2 2026 | -1.14 | -0.93 | +18.42% | $73.7M | ✅ Beat | -6.75% | +2.23% | -5.25% |
| 2026-02-05 | Q1 2026 | 0.02 | 0.22 | +1000.00% | $264.0M | ✅ Beat | -0.19% | -3.50% | -6.14% |
| 2025-11-25 | Q4 2025 | -0.05 | -0.18 | -260.00% | $256.5M | ❌ Miss | +23.34% | +39.08% | +49.95% |
| 2025-02-10 | Q1 2025 | -0.72 | -1.39 | -93.06% | $2.5M | ❌ Miss | -5.17% | +2.61% | -20.83% |
| 2024-11-26 | Q4 2024 | -0.92 | -1.37 | -48.91% | $0 | ❌ Miss | +24.23% | +9.79% | -9.93% |
| 2024-08-08 | Q3 2024 | -0.55 | -1.38 | -150.91% | $0 | ❌ Miss | -9.44% | -12.34% | -15.82% |
| 2024-02-06 | Q1 2024 | -0.82 | -1.24 | -51.22% | $3.6M | ❌ Miss | -4.67% | -9.88% | +0.00% |
Showing last 8 quarters.